caffeine has been researched along with Cerebral Palsy in 7 studies
Cerebral Palsy: A heterogeneous group of nonprogressive motor disorders caused by chronic brain injuries that originate in the prenatal period, perinatal period, or first few years of life. The four major subtypes are spastic, athetoid, ataxic, and mixed cerebral palsy, with spastic forms being the most common. The motor disorder may range from difficulties with fine motor control to severe spasticity (see MUSCLE SPASTICITY) in all limbs. Spastic diplegia (Little disease) is the most common subtype, and is characterized by spasticity that is more prominent in the legs than in the arms. Pathologically, this condition may be associated with LEUKOMALACIA, PERIVENTRICULAR. (From Dev Med Child Neurol 1998 Aug;40(8):520-7)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To systematically review the effects of caffeine on the development of cerebral palsy (CP)." | 9.41 | Caffeine and cerebral palsy: A systematic review of randomized controlled trials and cohort studies. ( Chaves Curioni, C; da Silva Ferreira, RC; Felderheimer da Silva, AC; Mocellin, MC, 2023) |
| " Although methylxanthines are widely used to prevent and treat apnea associated with prematurity and to facilitate extubation, there is uncertainty about the benefits and harms of different types of methylxanthines." | 9.41 | Methylxanthine for the prevention and treatment of apnea in preterm infants. ( Bruschettini, M; Davis, PG; Fiander, M; Marques, KA; Roehr, CC; Soll, R, 2023) |
| "3%) had been enrolled in the randomized, placebo-controlled Caffeine for Apnea of Prematurity trial between 1999 and 2004." | 9.16 | Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. ( Anderson, PJ; Asztalos, EV; Barrington, KJ; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2012) |
| "We randomly assigned 2006 infants with birth weights of 500 to 1250 g to receive either caffeine or placebo until therapy for apnea of prematurity was no longer needed." | 9.12 | Long-term effects of caffeine therapy for apnea of prematurity. ( Barrington, KJ; Davis, P; Doyle, LW; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2007) |
| "Postnatal administration of caffeine may reduce the risk of cerebral palsy (CP) in vulnerable low-birth-weight neonates." | 7.83 | Intake of Caffeinated Soft Drinks before and during Pregnancy, but Not Total Caffeine Intake, Is Associated with Increased Cerebral Palsy Risk in the Norwegian Mother and Child Cohort Study. ( Brantsæter, AL; Eichelberger, KY; Lie, RT; Meltzer, HM; Moster, D; Stoltenberg, C; Strandberg-Larsen, K; Tollånes, MC; Wilcox, AJ, 2016) |
| "To systematically review the effects of caffeine on the development of cerebral palsy (CP)." | 5.41 | Caffeine and cerebral palsy: A systematic review of randomized controlled trials and cohort studies. ( Chaves Curioni, C; da Silva Ferreira, RC; Felderheimer da Silva, AC; Mocellin, MC, 2023) |
| " Although methylxanthines are widely used to prevent and treat apnea associated with prematurity and to facilitate extubation, there is uncertainty about the benefits and harms of different types of methylxanthines." | 5.41 | Methylxanthine for the prevention and treatment of apnea in preterm infants. ( Bruschettini, M; Davis, PG; Fiander, M; Marques, KA; Roehr, CC; Soll, R, 2023) |
| "3%) had been enrolled in the randomized, placebo-controlled Caffeine for Apnea of Prematurity trial between 1999 and 2004." | 5.16 | Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. ( Anderson, PJ; Asztalos, EV; Barrington, KJ; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2012) |
| "We randomly assigned 2006 infants with birth weights of 500 to 1250 g to receive either caffeine or placebo until therapy for apnea of prematurity was no longer needed." | 5.12 | Long-term effects of caffeine therapy for apnea of prematurity. ( Barrington, KJ; Davis, P; Doyle, LW; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2007) |
| "Corticosteroids, intramuscular vitamin A and caffeine reduce the risk of bronchopulmonary dysplasia (BPD) in very-low-birth-weight infants." | 4.84 | Evidence-based neonatal drug therapy for prevention of bronchopulmonary dysplasia in very-low-birth-weight infants. ( Kirpalani, H; Millar, D; Roberts, R; Schmidt, B, 2008) |
| "Postnatal administration of caffeine may reduce the risk of cerebral palsy (CP) in vulnerable low-birth-weight neonates." | 3.83 | Intake of Caffeinated Soft Drinks before and during Pregnancy, but Not Total Caffeine Intake, Is Associated with Increased Cerebral Palsy Risk in the Norwegian Mother and Child Cohort Study. ( Brantsæter, AL; Eichelberger, KY; Lie, RT; Meltzer, HM; Moster, D; Stoltenberg, C; Strandberg-Larsen, K; Tollånes, MC; Wilcox, AJ, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| da Silva Ferreira, RC | 2 |
| Felderheimer da Silva, AC | 2 |
| Mocellin, MC | 2 |
| Chaves Curioni, C | 2 |
| Marques, KA | 1 |
| Bruschettini, M | 1 |
| Roehr, CC | 1 |
| Davis, PG | 2 |
| Fiander, M | 1 |
| Soll, R | 1 |
| Jensen, EA | 1 |
| Foglia, EE | 1 |
| Schmidt, B | 4 |
| Tollånes, MC | 1 |
| Strandberg-Larsen, K | 1 |
| Eichelberger, KY | 1 |
| Moster, D | 1 |
| Lie, RT | 1 |
| Brantsæter, AL | 1 |
| Meltzer, HM | 1 |
| Stoltenberg, C | 1 |
| Wilcox, AJ | 1 |
| Roberts, R | 1 |
| Millar, D | 1 |
| Kirpalani, H | 1 |
| Anderson, PJ | 1 |
| Doyle, LW | 2 |
| Dewey, D | 1 |
| Grunau, RE | 1 |
| Asztalos, EV | 1 |
| Tin, W | 2 |
| Moddemann, D | 1 |
| Solimano, A | 2 |
| Ohlsson, A | 2 |
| Barrington, KJ | 2 |
| Roberts, RS | 2 |
| Davis, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Methylxanthines in Very Low Birthweight Infants[NCT00182312] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 1999-10-31 | Completed | ||
| Pharmacokinetics (PK) and Safety of Caffeine in Neonates With Hypoxic Ischemic Encephalopathy Receiving Therapeutic Hypothermia[NCT05295784] | Phase 1 | 18 participants (Anticipated) | Interventional | 2024-06-30 | Not yet recruiting | ||
| A Prospective, Controlled Trial of Inhalation of Low Concentration of CO2 in Preterm Infants Not Responding to Caffeine for the Treatment of Apnea of Prematurity[NCT01911182] | Phase 2/Phase 3 | 7 participants (Actual) | Interventional | 2011-10-31 | Terminated (stopped due to Low recruitment rate) | ||
| Long-Term Effects On Sleep Of Methylxanthine Therapy For Apnea Of Prematurity[NCT01020357] | Phase 3 | 201 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| [NCT01066728] | Phase 2/Phase 3 | 87 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| A Randomized, Placebo-controlled Trial of Early Caffeine in Preterm Neonates[NCT03086473] | Phase 4 | 24 participants (Actual) | Interventional | 2017-02-01 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for caffeine and Cerebral Palsy
| Article | Year |
|---|---|
Caffeine and cerebral palsy: A systematic review of randomized controlled trials and cohort studies.
Topics: Caffeine; Cerebral Palsy; Child; Health Status; Humans; Infant; Infant, Newborn; Randomized Controll | 2023 |
Caffeine and cerebral palsy: A systematic review of randomized controlled trials and cohort studies.
Topics: Caffeine; Cerebral Palsy; Child; Health Status; Humans; Infant; Infant, Newborn; Randomized Controll | 2023 |
Caffeine and cerebral palsy: A systematic review of randomized controlled trials and cohort studies.
Topics: Caffeine; Cerebral Palsy; Child; Health Status; Humans; Infant; Infant, Newborn; Randomized Controll | 2023 |
Caffeine and cerebral palsy: A systematic review of randomized controlled trials and cohort studies.
Topics: Caffeine; Cerebral Palsy; Child; Health Status; Humans; Infant; Infant, Newborn; Randomized Controll | 2023 |
Methylxanthine for the prevention and treatment of apnea in preterm infants.
Topics: Apnea; Caffeine; Cerebral Palsy; Disabled Persons; Humans; Infant; Infant, Newborn; Infant, Prematur | 2023 |
Evidence-Based Pharmacologic Therapies for Prevention of Bronchopulmonary Dysplasia: Application of the Grading of Recommendations Assessment, Development, and Evaluation Methodology.
Topics: Anti-Bacterial Agents; Azithromycin; Bronchopulmonary Dysplasia; Caffeine; Cardiomyopathy, Hypertrop | 2015 |
Evidence-based neonatal drug therapy for prevention of bronchopulmonary dysplasia in very-low-birth-weight infants.
Topics: Bronchopulmonary Dysplasia; Caffeine; Cerebral Palsy; Clinical Trials as Topic; Evidence-Based Medic | 2008 |
2 trials available for caffeine and Cerebral Palsy
| Article | Year |
|---|---|
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
1 other study available for caffeine and Cerebral Palsy
| Article | Year |
|---|---|
Intake of Caffeinated Soft Drinks before and during Pregnancy, but Not Total Caffeine Intake, Is Associated with Increased Cerebral Palsy Risk in the Norwegian Mother and Child Cohort Study.
Topics: Adult; Caffeine; Carbonated Beverages; Cerebral Palsy; Female; Humans; Infant, Low Birth Weight; Inf | 2016 |